Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPRS1 | P07814 | 3/20 | 0.79 |
| ▸ | DHODH | Q02127 | 3/20 | 0.78 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | PPARG | P37231 | 3/20 | 0.68 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | MC4R | P32245 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | PTGES | O14684 | 1/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CASP7 | P55210 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5530291 | 0.93 | EPRS1 (0.85) | EPRS1DHODHRXFP1MEN1KMT2A | |
| SCHEMBL12237494 | 0.93 | RXFP1 (0.75) | EPRS1DHODHRXFP1MEN1KMT2A | |
| SCHEMBL1899098 | 0.92 | RXFP1 (0.79) | EPRS1DHODHRXFP1MEN1KMT2A | |
| SCHEMBL5838639 | 0.91 | DHODH (0.74) | EPRS1DHODHRXFP1MEN1KMT2A | |
| SCHEMBL18320549 | 0.91 | DHODH (0.76) | EPRS1DHODHRXFP1MEN1KMT2A | |
| SCHEMBL7814193 | 0.90 | GAA (0.71) | EPRS1DHODHRXFP1MEN1KMT2A | |
| SCHEMBL18320787 | 0.89 | KDM4E (0.71) | EPRS1DHODHRXFP1MEN1KMT2A | |
| SCHEMBL5792900 | 0.88 | DHODH (0.78) | EPRS1DHODHMEN1KMT2AGAA | |
| SCHEMBL117388 | 0.88 | EPRS1 (1.00) | EPRS1DHODHRXFP1MEN1KMT2A | |
| SCHEMBL117422 | 0.88 | PTGES (0.84) | EPRS1DHODHKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-8921369-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921369-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8877707-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2010065674-A9 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2011149856-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2010065674-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | EPRS1 13/4885DHODH 2635/4885RXFP1 1205/4885 |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | EPRS1 1875/4885DHODH 3751/4885RXFP1 4668/4885 |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | EPRS1 1657/4885DHODH 3567/4885RXFP1 4688/4885 |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | EPRS1 1657/4885DHODH 3567/4885RXFP1 4688/4885 |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | EPRS1 1657/4885DHODH 3567/4885RXFP1 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.